HeartSciences Inc. Warrant financials
$0.0437−18.62%
Close Sep 22, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '27 Jul 31 | Q4 '26 Apr 30 | Q3 '26 Jan 31 | Q2 '26 Oct 31 | Q1 '26 Jul 31 | Q4 '25 Apr 30 | Q3 '25 Jan 31 | Q2 '25 Oct 31 | Q1 '25 Jul 31 | Q4 '24 Apr 30 | Q3 '24 Jan 31 | Q2 '24 Oct 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1K | $0.00 | $0.00 | $2.4K | $1.9K | $4.3K | $0.00 | $0.00 | $0.00 | $0.00 | $14.7K | $3.9K |
| Gross profit | $1.3K | $0.00 | $0.00 | $1.4K | $1.1K | $2.5K | $0.00 | $0.00 | $0.00 | $0.00 | $10.1K | $2.4K |
| Gross margin | 63.8% | — | — | 58.3% | 60.0% | 56.8% | — | — | — | — | 69.0% | 61.0% |
| Operating income | -$2.9M | -$2.5M | -$1.9M | -$2.1M | -$1.9M | -$1.9M | -$2.4M | -$2.0M | -$2.1M | -$1.9M | -$1.5M | -$1.6M |
| Net income | -$3.2M | -$2.8M | -$2.0M | -$2.4M | -$2.1M | -$2.1M | -$2.5M | -$2.1M | -$2.1M | -$1.8M | -$1.6M | -$1.7M |
| Net margin | −151064.0% | — | — | −97179.4% | −108157.6% | −48145.5% | — | — | — | — | −11182.4% | −44830.2% |
| Diluted EPS | $-0.86 | $-0.85 | $-0.63 | $-0.85 | $-1.58 | $-1.95 | $-2.57 | $-2.27 | $-2.64 | $-2.84 | $-3.01 | $-15.92 |
| EBITDA | -$2.9M | -$2.5M | -$1.9M | -$2.1M | -$1.9M | -$1.9M | -$2.4M | -$2.0M | -$2.1M | -$1.9M | -$1.5M | -$1.6M |
| Operating cash flow | -$1.3M | -$1.7M | -$1.5M | -$2.3M | -$2.0M | -$1.6M | -$1.6M | -$2.2M | -$2.0M | -$1.6M | -$2.1M | -$988.2K |
| Free cash flow | -$1.3M | -$1.7M | -$1.5M | -$2.3M | -$2.0M | -$1.6M | -$1.6M | -$2.2M | -$2.0M | -$1.6M | -$2.1M | -$995.0K |
| Diluted shares | 3.7M | 3.3M | 3.2M | 2.8M | 1.3M | 1.1M | 1.0M | 0.9M | 0.8M | 0.7M | 0.5M | 0.1M |
Balance sheet
| Period end | Jul 31 | Jun 30 | Apr 30 | Jan 31 | Dec 31 | Oct 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.9K | $1.7M | $1.7M | $3.4M | $1.1M | $2.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Total debt | $4.0M | $4.0M | $4.0M | $3.7M | $2.7M | $660.3K |
| Total assets | $3.7M | $5.3M | $5.3M | $7.6M | $4.2M | $6.0M |
| Total liabilities | $5.8M | $5.0M | $5.0M | $4.9M | $4.0M | $1.8M |
| Shareholders' equity | -$2.0M | $226.1K | $226.1K | $2.7M | $205.2K | $4.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology